CLINICAL_TRIALS
trial_result
· 2022-07-12
Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD [Phase 3]
Summary
Phase 3 clinical trial evaluating SPN-812 (viloxazine extended-release) in adults with ADHD has completed; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2022-07-12